Avivagen Inc, a life sciences corporation that focuses on developing and commercialising products for livestock, companion animal and human applications has announced it has signed a large-scale purchase agreement to supply its largest customer in Asia
According to Avivagen, the order comprises a 6.3-tonne order of OxC-beta Livestock, a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The company said that the shipment represents a 43% increase in size over the customer’s previous order and continues a trend of increased reorder size among this and other OxC-beta customers worldwide.
Kym Anthony, CEO, Aviagen said, “We’re extremely pleased to see the continued growth of this important customer in Asia, one of the most important regions worldwide for livestock feed production. We believe that the fact that Avivagen’s customers continue to increase order size for OxC-beta amid a global pandemic is a clear sign of the positive impact that integration of our products can have on our customer’s bottom line. We’re excited by the growth potential ahead of us in both Asia and around the world.”
Avivagen said that the OxC-beta technology is derived from discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through the support of immune function, the technology provides a non-antibiotic means of promoting health and growth. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.
According to the company, numerous international livestock trials with poultry and swine using OxC-beta have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
